| P2093 | author name string | X Lin | |
| | M Puig | |
| | C Montagut | |
| | J Bellmunt | |
| | R Salazar | |
| | C Gómez-Martín | |
| | J M Tursi | |
| | J A Núñez | |
| | M J Lechuga | |
| | R Khosravan | |
| | M Gil-Martín | |
| P2860 | cites work | Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma | Q74397589 |
| | Gastric cancer | Q84089902 |
| | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Clinical pharmacokinetics and administration of established platinum drugs | Q33948752 |
| | Cancer of the esophagogastric junction | Q34348338 |
| | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 |
| | Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 |
| | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34620678 |
| | Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3 | Q35558123 |
| | Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis | Q35582348 |
| | Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells | Q36308484 |
| | Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group | Q37037994 |
| | Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. | Q37468358 |
| | Clinical pharmacology of 5-fluorouracil | Q38631279 |
| | Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer | Q40623012 |
| | SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer | Q40647641 |
| | Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines | Q41057733 |
| | Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials | Q42181610 |
| | An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. | Q42798763 |
| | Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy? | Q42846225 |
| | Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study | Q43147962 |
| | SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo | Q44280921 |
| | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 |
| | SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model | Q44720331 |
| | High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets | Q44772602 |
| | Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. | Q50882866 |
| | Gastric cancer | Q57758203 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| | cisplatin | Q412415 |
| P304 | page(s) | 390-398 | |
| P577 | publication date | 2012-05-22 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer | |
| P478 | volume | 31 | |